Zhongtai Securities Co.Ltd(600918) the small and medium-sized market research team combed and studied the companies approved by the CSRC for IPO registration in the latest week of gem and science and Innovation Board (2022.02.14-2022.02.20), and launched the weekly special research report on new shares. This weekly report involves 2 enterprises to be issued on the science and innovation board and 4 enterprises to be issued on the gem:
Kechuang board:
Jingwei Hengrun (a21257. SH): the company is a comprehensive electronic system technology service provider. Its main business focuses on automotive electronic products, focusing on providing electronic products, R & D services and solutions and overall solutions for high-level intelligent driving for customers in the fields of automobile, high-end equipment and unmanned transportation. The compound annual growth rates of the company’s revenue and net profit from 2018 to 2020 were 26.92% and 88.34% respectively, with outstanding growth capacity. The company is expected to benefit from the recovery of the automobile industry, the penetration and upgrading of automatic driving technology and the growth of intelligent vehicle demand. The shipment volume of the company’s products is expected to rise significantly. After listing, the company needs to give full play to the role of raising funds and the capital platform value of listed companies, so as to further enhance the company’s competitive advantage, so as to enhance the company’s industry position.
Haichuang Pharmaceutical (a21066. SH): the company is an international innovative drug enterprise based on deuterated technology and protac targeted protein degradation technology platform, aiming at developing best in class and first in class drugs with major clinical needs. The two core products under research of the company have strong R & D leading advantages. At present, all products of the company are in the R & D stage, of which hc-1119 and hp501 have entered the clinical stage, but they have not yet achieved commercialization and product sales revenue. In the future, the company will continue to increase investment in R & D, and the cumulative loss will continue to expand. The company has a broad market space. Hc-1119 and hp501 are expected to take the lead in commercialization. Benefiting from the expansion of the scale of China’s innovative drug industry, it will further improve the penetration rate and help the company gradually realize profitability.
Gem:
Prius (a20567. SZ): the company is an enterprise that provides customers with SMO whole process services. As the only Chinese mainland SMO company to be selected as the Asia Pacific clinical trial alliance, after many years of industry precipitation and accumulation, the company has rich experience in SMO project implementation, especially in cancer, viral hepatitis and endocrine diseases with a large competitive advantage. The compound annual growth rates of the company’s revenue and net profit from 2017 to 2020 were 43.98% and 30.08% respectively. With the national promotion of pharmaceutical system reform, the R & D investment in the pharmaceutical market will continue to increase in the future, and the raised investment projects will greatly improve the company’s service capacity and enhance its core competitiveness. The company is expected to further improve its industry strength and market position.
Huarong chemical (a20699. SZ): the company is an advanced enterprise committed to the green recycling and comprehensive utilization of potassium hydroxide. Its main product is potassium hydroxide. The compound annual growth rates of the company’s revenue and net profit from 2017 to 2020 were 5.53% and 155.65% respectively. With the increasing demand for downstream potassium hydroxide, the raised investment project promotes the improvement of the company’s overall level of technological R & D capability and independent innovation, and the enhancement of the production capacity and service capacity of core products. The company is expected to further improve its industry strength and market position.
Fujilai (a20598. SZ): the company is a high-tech enterprise mainly engaged in the R & D, production and sales of pharmaceutical intermediates, APIs and raw materials of health products. The compound annual growth rates of the company’s revenue and net profit from 2017 to 2020 were 8.30% and 22.17% respectively. With the improvement of residents’ living standards and health awareness, the market of API, pharmaceutical intermediates and health products will continue to develop positively. With the enhancement of R & D and production capacity of the company promoted by the raised investment project, R-Lipoic acid produced by the green process of new enzymatic synthesis will have stronger biological activity. The company is expected to further improve its industry strength and market position.
Heshun Technology (a16277. SZ): the company is a high-tech enterprise focusing on the R & D, production and sales of differentiated and functional biaxially stretched polyester film (BOPET film). It can produce polyester film products of various specifications, models and different uses according to the differentiated needs of customers. The compound annual growth rates of the company’s revenue and net profit from 2017 to 2020 were 37.02% and 64.47% respectively, with outstanding growth capacity. The rapid development of downstream new energy vehicles and 5g consumer electronics will provide a broad market space for the polyester film field. With the raised investment projects promoting the improvement of the company’s production and R & D capacity, the new optical film base film products will effectively enrich the company’s product categories, and the company is expected to further improve its industry strength and market position.
Risk tips: 1) the corresponding companies still have the risk of failure to be listed due to special events; 2) The research is only based on the prospectus (Registration draft) and other public materials of the corresponding company, which can not fully reflect the latest situation of the company.
